In recent months, the DTRF learned from patients that the 50mg tablet of Ogsiveo® (nirogacestat) will no longer be available after 2024. The DTRF contacted SpringWorks Therapeutics to advocate for patients who are currently receiving the 50mg tablet.
Last week, the SpringWorks Therapeutics team confirmed that the 50mg tablet of Ogsiveo® will, in fact, no longer be available as of January 1, 2025.
New blister packs are available for the FDA-approved 100mg and 150mg doses of Ogsiveo®. Click here to read the statement SpringWorks provided to the DTRF.
The DTRF advises that patients talk to their physician, pharmacist, or other trusted medical team member with any questions. Medical professionals are encouraged to reach out to the SpringWorks Medical Information team on behalf of their patients to receive answers to questions regarding this change.
Follow the steps below with the help of your medical team to receive the most timely and accurate Ogsiveo® information:
- Bring your Ogsiveo® dosage questions or concerns directly to a trusted member of your medical team (including your physicians and pharmacists).
- Ask your trusted medical professional to contact a SpringWorks Medical Information team member directly at 1-888-400-7989 or medinfo@springworkstx.com.
- Request that your medical professional ask specific, direct questions when discussing Ogsiveo® so that clear recommendations can be relayed back to their patient(s).
Please note: Only medical professionals, including physicians, pharmacists, or other medical team members, are permitted to discuss Ogsiveo® dosage questions or concerns with the SpringWorks Medical Information team.
If you are a desmoid tumor patient needing educational, emotional, or financial support and resources while taking Ogsiveo®, you can connect directly with SpringWorks CareConnections™.
If you’ve been impacted by the 50mg tablet no longer being available, please contact the DTRF at info@dtrf.org to share your experience and help us continue advocating for desmoid tumor patients.
